Göran Ando, M.D.
Senior Advisor, London- B.A.
- Uppsala University, Sweden
- M.D.
- Linköeping University, Sweden
Göran Ando, M.D., has over 35 years of experience as a senior executive for international pharma and biotech companies. Dr. Ando began his career in the pharmaceutical industry in 1978 as Medical Director of Pfizer AB, progressing to Director, Clinical Research with Pfizer International in the U.S. Dr. Ando then became VP, Medical and Scientific Affairs at Bristol-Myers and returned to Sweden as President of the Astra Research Centre. Between 1989 and 1995, he held various senior appointments at Glaxo, including Research & Development Director for Glaxo Group Research.
In 1995, Dr. Ando joined Pharmacia AB in Sweden as Executive Vice President and Deputy CEO, moving to the U.S. in 1997 to lead R&D with additional responsibilities for manufacturing, IT, business development and M&A. During his eight-year tenure as Head of R&D at Pharmacia/Pharmacia & Upjohn, 17 NCEs were approved by the US FDA. Most recently, Dr. Ando was CEO of CellTech Group PLC in the United Kingdom, one of the most successful European biotech companies, until it was acquired by UCB Pharma for $3 billion in 2005.
In addition to the Essex Woodlands portfolio company boards on which he serves, Dr. Ando is currently Vice Chairman of the Board at Novo Nordisk A/S, Copenhagen and Vice Chairman of S*BIO Pte Ltd. in Singapore and is a Member of the Board of Directors of the following companies: Novo A/S, Copenhagen, EDBI Pte Ltd, Singapore, and Archimedes Pharma, United Kingdom. Dr. Ando is also a member of the Scientific Advisory Board at Bausch & Lomb, USA and is a Founding Fellow of the American College of Rheumatology in the United States.
Dr. Ando joined Essex Woodlands as Senior Advisor, based in the London office, in January 2007.
